Agios Pharmaceuticals Inc (AGIO) financials
Agios Pharmaceuticals revenue and earnings by year
Agios Pharmaceuticals's revenue was $54.0 million in the fiscal year to December 31, 2025, up 48.0% from the year before. Net income was -$413 million, -764.0% of revenue. Since the fiscal year to December 31, 2016, revenue has shrunk 2.8% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 7 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|
| Revenue | 54 | 36 | 27 | 14 | 94 | 43 | 70 |
| Revenue growth | 48.0% | 36.1% | 88.4% | -84.9% | 119.4% | -38.5% | — |
| Gross profit | 48 | 32 | 24 | 13 | 93 | — | — |
| Gross margin | 88.3% | 88.6% | 89.3% | 88.0% | 98.5% | — | — |
| Operating income | -472 | 463 | -391 | -251 | -362 | -321 | -201 |
| Operating margin | -873.9% | 1269.7% | -1459.5% | -1765.0% | -384.0% | -745.8% | -287.6% |
| Net income | -413 | 674 | -352 | -232 | -346 | -315 | -198 |
| Net margin | -764.0% | 1845.9% | -1312.6% | -1627.8% | -366.6% | -731.6% | -284.0% |
| Diluted EPS | -$7.12 | $11.64 | -$6.33 | -$4.23 | -$6.03 | -$6.74 | -$5.06 |
| Free cash flow | -377 | -391 | -296 | -313 | -311 | -290 | 29 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open AGIO in Markets.
See also: AGIO returns
No forecast, no recommendation. This page describes Agios Pharmaceuticals Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.